Inovio Launches Underwritten Offering of Common Stock and Warrants to Fund INO-3107 Launch Prep
INO is trading near its 52-week low of $0.95 (13% below the low).
Summary
Inovio launched an underwritten public offering of common stock and warrants, with preliminary Q2 cash of only $36.7 million. The highly dilutive raise is critical to fund preparations for a potential INO-3107 launch ahead of the October 30 PDUFA date.
Key Events · Financing and Capital Events · INO
-
Underwritten Offering Launched
Inovio is offering shares of common stock in fixed combinations with warrants (each share accompanied by a warrant to purchase two shares). The warrants are immediately exercisable with a five-year term. The number of shares and pricing are not yet set in this preliminary prospectus supplement.
-
Preliminary Cash of $36.7M
As of June 30, 2026, Inovio estimates cash and cash equivalents of approximately $36.7 million, underscoring the urgent need for capital ahead of the October 30, 2026 PDUFA date for INO-3107.
-
Use of Proceeds
Net proceeds will be used primarily for preparing for a potential commercial launch of INO-3107, conducting a confirmatory trial if required, development of the clinical pipeline, and general corporate purposes.
-
Highly Dilutive Structure
The offering includes warrants to purchase two shares for each share sold, creating significant potential dilution. The deal is being executed near the 52-week low, reflecting the company's distressed financial position.
Analysis · INO · Life Sciences
Inovio is tapping its $300M shelf with an underwritten public offering of common stock and warrants. The deal is structured as fixed combinations of one share plus a warrant to buy two more shares, with the warrants immediately exercisable for five years. The company disclosed a preliminary cash balance of just $36.7 million as of June 30, 2026 — a razor-thin runway with the PDUFA date for its lead drug INO-3107 on October 30, 2026. Proceeds are earmarked for commercial launch preparation, a confirmatory trial if required, and pipeline development. The offering is highly dilutive at current prices near the 52-week low, but the capital is essential to bridge the company to a potential approval. The warrant overhang and deeply discounted structure reflect the company's distressed position and urgent need for cash.
At the time of this filing, INO was trading at $0.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $85.6M. The 52-week trading range was $0.95 to $2.98. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.